Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the second quarter and six months ended June 30, 2009. InterMune reported a net loss for the second quarter of 2009 of $36.7 million, or $0.81 per share, compared with a net loss of $29.6 million, or $0.76 per share, in the second quarter of 2008.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "The last several months have been exceptionally productive for InterMune and the coming months promise to be even more so. Regarding pirfenidone, we have made excellent progress on the preparation of our New Drug Application (NDA) for pirfenidone which we now expect to submit in the fourth quarter. It has taken more time than we anticipated to integrate the advice of a host of external expert advisors and to take every possible step to develop the strongest possible file that positions us for potential approval in the first review cycle. Our Marketing Authorization Application (MAA) is also progressing very well; we had a successful pre-submission meeting with the EMEA in July and we expect to submit the MAA for pirfenidone in the first quarter of 2010."

Mr. Welch continued, "Regarding ITMN-191 (R7227), we announced exciting news today on several important aspects of the program, specifically: the successful completion of six-month and nine-month chronic toxicology studies in rats and monkeys, respectively which clear the way for our Phase 2 and Phase 3 clinical programs; our expectation that our partner Roche will enroll the first patient in our Phase 2b study of ITMN-191 in combination with standard of care in August; our plans to start a Phase 1b MAD study of ITMN-191 in combination with low dose ritonavir in HCV patients in the thi
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015  For about a century, ... their ability to utilize and catabolize glucose at ... cells is called the ,Warburg phenomenon", that is ... high oxygen presence, leading to enhanced lactate generation. ... still choose glucose fermentation. A variety of such ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Dr. Robert ... and chemical toxicity carries implications for advancing the creation ... 28 at National University , the second-largest private, ... by Dr. Hanzlik, a professor at the University of ... and drug design, starts at 5 p.m. and takes ...
(Date:4/27/2015)... NORTH BRUNSWICK, New Jersey , ... Pharmaceuticals, société de découverte médicamenteuse spécialisée ... d,agents antibiotiques destinés à soigner les ... annoncé aujourd,hui la présentation de données ... clinique majeur, le TXA709, dans la ...
(Date:4/27/2015)... , April 27, 2015 SynGen Inc., a ... instrument systems that harvest stem and progenitor cells from ... culture, announced today that it has added three new ... and Cord Blood Business Units focus on product commercialization. ... team as its Vice President and Chief Financial Officer.  ...
Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6SynGen Inc. Expands Its Management Team 2
... for Progress MADISON, Wis. Members of the ... story of an emerging trend in the corporate world ... , ,Lori Silverman, owner of the consulting firm Partners ... Critical Shift, explained how simply following a story arc ...
... MADISON, Wis. A nurse keys a 10-milliliter-per-hour dose ... makes a simple mistake, accidentally keying in an overdose ... to receive 25 ml of a different drug, but ... like these occur every day in hospitals across the ...
... Sonic Foundry, a provider of rich-media systems and software, ... the company has announced. , ,Sonic Foundry and media ... power Courtroom Connect's new Virtual Law Viewer ... ten Sonic Foundry MediaSite presentation recorders with the BxVideo ...
Cached Biology Technology:Storytelling makes a comeback in an unlikely place 2Storytelling makes a comeback in an unlikely place 3UW Hospital and Clinics install smart intravenous pumps 2UW Hospital and Clinics install smart intravenous pumps 3Streaming video could make courtrooms into Internet conference calls 2
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... promising new class of drug designed to target the ... system, some of the HCV strains being treated exhibited ... team of Florida State University biologists, chemists and biomedical ... identify the drug-resistant HCV strains and the molecular-level mechanisms ...
... powerful new ability to engineer the flavor and aroma of ... publishing the most comprehensive deciphering of the beer,s "proteome" ever ... that make beer "beer") appears in ACS, monthly Journal ... say they were inspired to do the research by a ...
... has "significant" potential for preventing cardiomyopathy, a form of heart ... with diabetes, scientists have concluded in a new study. Their ... high risk for diabetic cardiomyopathy, appears in ACS, bi-weekly ... and colleagues note that people with diabetes have at least ...
Cached Biology News:Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
... The new TC-412 thermal cycler, flexible on your ... is a high performance, high sample throughput instrument ... , Flexible block format: The truly user-friendly ... exchanged in a matter of seconds without the ...
... a buffered anti-freeze environment for enzyme conjugated ... liquid, low viscosity solution at -20C ... and sampling is convenient , Contains ... storage Protect enzyme conjugates during storage ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
A collection of 42 spots with normal tissues from different organs of C57 mice, rat and human....
Biology Products: